Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that members of its management team will participate in two investor conferences in August and September 2026. President and Chief Executive Officer Dr. Seth Lederman will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Aug. 11 from 1:30 p.m. to 1:55 p.m. ET. The company also said Lederman will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Sept. 16. These events provide Tonix an opportunity to discuss its business and engage with the investment community.
This announcement is significant for investors as it signals Tonix's proactive approach to maintaining visibility and transparency with the financial community. The company is at a pivotal juncture, having recently received approval for its flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. The approval marks a major milestone for the company, and the investor conferences offer a platform to highlight the commercial launch and ongoing clinical development programs.
Tonix is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. The company's CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace SymTouch and Tosymra. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company's CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The investor conferences come at a time when Tonix is expanding its commercial footprint and advancing its pipeline. The company's participation in these high-profile events underscores its commitment to communicating its strategic vision and progress to shareholders and potential investors. The fireside chat and one-on-one meetings will allow management to provide deeper insights into the company's growth strategies, clinical data, and market opportunities.
For more information about the company and its latest news, visit the company's newsroom at https://ibn.fm/TNXP. The full press release is available at https://ibn.fm/DKFAC.
As Tonix continues to navigate the complexities of the biotech market, its engagement with the investment community through these conferences is a positive indicator of its dedication to transparency and growth. The company's focus on addressing unmet medical needs in CNS and immunology positions it for potential long-term success, making its presentations at these events of interest to current and prospective shareholders.
